Integrated Screening Key for HIV, Syphilis, Hepatitis B Elimination

The European AIDS Treatment Group (EATG) has highlighted a significant publication from the Clinton Health Access Initiative (CHAI): the second edition of its 'Triple Elimination Series' Market Memo. Released on March 30, 2026, this memo is crucial for understanding the diagnostic landscape in the global effort to prevent the vertical transmission of HIV, syphilis, and hepatitis B (HBV) from mother to child. These three infections collectively cause substantial and preventable infant morbidity, mortality, and stillbirths annually, particularly in regions like sub-Saharan Africa, and pose a significant public health challenge worldwide. The CHAI market memo specifically focuses on the implementation of integrated screening in antenatal care settings. It provides an in-depth assessment of the emerging market for triple HIV/syphilis/HBV combination tests, which offer a streamlined approach to diagnosis. Furthermore, it models the potential market for these tests under various pricing and financing scenarios, drawing critical insights from implementation experiences across 16 countries. A key finding of CHAI's analysis is that while screening coverage for HIV and syphilis in antenatal care has seen considerable improvements, HBV screening significantly lags, reaching only about 44% across CHAI's focus countries – roughly half the rate observed for HIV and syphilis. This disparity underscores a critical gap in the comprehensive prevention strategy. The memo argues that integrated screening for all three diseases offers a practical and efficient path forward to address these gaps and accelerate progress towards global elimination targets. However, the path to achieving widespread triple elimination screening is fraught with two primary uncertainties: the availability of adequate financing and the eventual price of the triple combination tests. While new diagnostic tools are entering the market, promising to simplify testing workflows and reduce missed infections, health systems globally are simultaneously struggling with shrinking donor budgets and limited domestic funding allocated to maternal health programs. This financial squeeze could jeopardize the scale-up of these vital screening programs. CHAI's report emphasizes that at higher price points, budget constraints could render triple tests unviable for widespread adoption, risking a reduction in overall testing volumes and potentially reversing the hard-won gains in HIV and syphilis screening coverage. Alarmingly, in scenarios without affordable triple tests, HBV screening is projected to decline sharply under funding pressure, with little chance of recovery. CHAI's analysis, which combines qualitative research with quantitative market modeling across three financing scenarios, provides important insights for various stakeholders, including policymakers, procurement agencies, and global health funders. It highlights that demand for integrated HIV, syphilis, and HBV screening in antenatal care is strong across all 16 countries assessed, with these nations expressing willingness to consider adopting a triple combination test. Nevertheless, the report also points out that the variation in preferred test formats underscores the need for a diversified product pipeline to meet diverse country needs. Furthermore, it stresses that scale-up timelines for these integrated screening programs require deliberate acceleration and coordinated efforts. The 'triple elimination' strategy itself is a recognized and crucial global health goal, supported by various international health bodies and research. For instance, the World Health Organization's Regional Framework for Triple Elimination of Mother-to-Child Transmission of HIV, Hepatitis B and Syphilis in Asia and the Pacific 2018–2030, endorsed by member states, provides a coordinated approach to prevent these infections using shared Maternal, Newborn and Child Health (MNCH) platforms. Research in countries like Uganda also explores the facilitators and barriers to delivering integrated care for triple elimination, highlighting the importance of trained health workers, district leadership engagement, and community health worker involvement, while pointing to challenges like drug and commodity stock-outs. These corroborating sources underscore the global relevance and urgency of CHAI's findings. To effectively realize the potential of integrated screening and triple combination tests, the memo calls for coordinated action across several fronts: evidence generation, financing, implementation, and proactive market shaping to achieve accessible price points. The Clinton Health Access Initiative is a non-profit organization dedicated to strengthening health systems and expanding access to care and treatment for various illnesses, including HIV/AIDS and malaria. The European AIDS Treatment Group is a patient-led NGO advocating for people living with or affected by HIV/AIDS and co-infections in the WHO Europe region. Their collaboration in disseminating this memo underscores the importance of this market analysis for global public health efforts. For an audience in India, this news holds significant relevance. India faces a considerable burden of HIV, syphilis, and hepatitis B, and the prevention of mother-to-child transmission is a national public health priority. The challenges and solutions discussed in the CHAI memo – particularly regarding integrated screening in antenatal care, the need for affordable diagnostics, and robust financing mechanisms – are directly applicable to India's public health strategies and its efforts to improve maternal and child health outcomes. Addressing these issues effectively could lead to a substantial reduction in infant morbidity and mortality related to these preventable infections in India.

Frequently Asked Questions

Read Full Story on Quick Digest